Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone.

Abstract

BACKGROUND Bullous pemphigoid is an autoimmune blistering disease, with relapses, isolated or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Joint manifestations rapidly respond to small or moderate doses of corticosteroids, whereas skin manifestations usually respond to antimalarial drugs. CASE REPORT We describe the clinical case of an 11-year-old girl with SLE. She showed bullous skin lesions with arthralgia, mild proteinuria, resolved after steroid treatment. At the tapering of her prednisone dose, the patient had new skin lesions requiring an increased dose of prednisone. She started dapsone at the dosage of 1 mg/kg/day, maintaining low dose prednisone; this treatment was successfully followed by the dramatic disappearance of skin lesions and limb pain. CONCLUSIONS Bullous skin lesions can represent the first clinical presentation of pediatric SLE and could influence the treatment and the outcome of these patients. This case showed an atypical course as both skin manifestations and arthritis promptly and persistently resolved with dapsone without the use of high-dose glucocorticoids. Only a few cases of patients with SLE associated with bullous pemphigoid have been reported in the literature, and very few in the pediatric population.

• Authors: Maria Cristina Maggio, Giovanni Corsello, Eugenia Prinzi, Rolando Cimaz
• Journal: The American journal of case reports (Am J Case Rep) Vol. 18 Pg. 317-319 (03 29 2017) ISSN: 1941-5923 [Electronic] United States
• PMID: 28352068 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antimalarials
• Dapsone

Topics

• Antimalarials (therapeutic use)
• Child
• Dapsone (therapeutic use)
• Female
• Humans
• Lupus Erythematosus, Systemic (drug therapy)
• Pemphigoid, Bullous (drug therapy)